ClinicalTrials.gg
CompletedNCT07929818Updated Nov 10, 2026

Intrathecal Dexmedetomidine 5 mcg Versus 10 mcg With Bupivacaine for Infra-umbilical Surgery

A Phase 4 interventional study of Dexmedetomidine 5 micrograms (intrathecal) and Dexmedetomidine 10 micrograms (intrathecal) in Spinal Anesthesia, Intraoperative Hypotension and Bradycardia, sponsored by Hussain Aziz Bhatti. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Hussain Aziz Bhatti · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Aug 2025, registered Oct 2026).
Updated Nov 10, 2026Newly registeredGo to Updates ↓
Phase
Phase 4
Study type
Interventional
Enrollment
544
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This randomized controlled trial compares two isovolumetric intrathecal doses of dexmedetomidine (5 micrograms and 10 micrograms) added to 12.5 mg hyperbaric bupivacaine for spinal anaesthesia in adults undergoing elective infra-umbilical surgery. A total of 544 patients are randomly allocated into two groups of 272 each. The incidence of intraoperative hypotension is the primary outcome. Intraoperative bradycardia, number of hypotensive and bradycardic episodes, rescue drug use and time to two-segment regression of the sensory block are secondary outcomes.

Read the detailed description

Subarachnoid block is a single-shot technique with a limited duration of anaesthesia and analgesia. Dexmedetomidine, a selective alpha-2 adrenergic agonist, prolongs the sensory and motor block when added to intrathecal local anaesthetic without causing respiratory depression, but it may cause dose-dependent bradycardia and hypotension. Published trials comparing 5 micrograms and 10 micrograms intrathecal dexmedetomidine report conflicting rates of hypotension and bradycardia, so the lowest effective dose that keeps haemodynamics stable remains unclear.

After approval from the Ethics Research Review Committee of PIMS and written informed consent, 544 ASA I-II adults aged 18-80 years scheduled for elective infra-umbilical surgery under spinal anaesthesia are randomly allocated by computer-generated random numbers into two groups of 272 each. Group L receives 5 micrograms dexmedetomidine and Group H receives 10 micrograms dexmedetomidine; each dose is diluted with normal saline to 1 ml and added to 12.5 mg of 0.5% hyperbaric bupivacaine, so that both injectates have the same volume. Patients are blinded to group allocation.

Heart rate and mean arterial pressure are recorded at baseline and throughout surgery. Intraoperative hypotension is defined as a fall in mean arterial pressure of more than 20% from baseline and is treated with intravenous phenylephrine. Intraoperative bradycardia is defined as a heart rate below 60 beats per minute and is treated with intravenous atropine. The number of hypotensive and bradycardic episodes, total phenylephrine and atropine doses, highest level of sensory block and time to two-dermatome regression of the sensory block are recorded.

Data are analysed in SPSS version 26.0. Normality of quantitative data is checked by the Shapiro-Wilk test. Categorical outcomes are compared by the chi-square test and quantitative outcomes by the independent sample t-test. Effect modifiers (age, gender, ASA class, type of surgery and level of sensory block) are controlled by stratification and multivariable logistic regression. A p-value of less than 0.05 is taken as significant.

02

Conditions studied

  • Spinal Anesthesia
  • Intraoperative Hypotension
  • Bradycardia

Keywords

  • Dexmedetomidine
  • Intrathecal adjuvant
  • Bupivacaine
  • Subarachnoid block
  • Hypotension
  • Infra-umbilical surgery
03

In context

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

This study's enrollment of 544 is above the median of 100 across 187 interventional studies indexed under Bradycardia.

Browse Bradycardia studies →

Lead sponsor

This is the only study on the registry with Hussain Aziz Bhatti as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years
  • I or II
  • Elective infra-umbilical surgery under spinal anaesthesia
  • 18 to 30 kg/m2
  • Willing to give written

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to dexmedetomidine or local anaesthetics
  • Cardiovascular instability (arrhythmia, severe hypertension or hypotension)
  • Significant hepatic, renal or neurological disease
  • to spinal anaesthesia (coagulopathy, infection at the puncture site)
  • Pregnancy or lactation
  • Current use of alpha-2 agonists or antagonists
  • History of substance abuse or chronic pain
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
544 participants (actual)

Study arms

  • Experimental
    Group L: Dexmedetomidine 5 mcg

    Spinal anaesthesia with 12.5 mg of 0.5% hyperbaric bupivacaine plus dexmedetomidine 5 micrograms diluted to 1 ml with normal saline.

    Drug: Dexmedetomidine 5 micrograms (intrathecal) · Drug: Hyperbaric bupivacaine 0.5%

  • Active comparator
    Group H: Dexmedetomidine 10 mcg

    Spinal anaesthesia with 12.5 mg of 0.5% hyperbaric bupivacaine plus dexmedetomidine 10 micrograms diluted to 1 ml with normal saline.

    Drug: Dexmedetomidine 10 micrograms (intrathecal) · Drug: Hyperbaric bupivacaine 0.5%

Interventions

  • DrugDexmedetomidine 5 micrograms (intrathecal)

    Dexmedetomidine 5 micrograms diluted with normal saline to 1 ml and added to 12.5 mg hyperbaric bupivacaine, injected intrathecally at L3-L4 or L4-L5 in the sitting position.

  • DrugDexmedetomidine 10 micrograms (intrathecal)

    Dexmedetomidine 10 micrograms diluted with normal saline to 1 ml and added to 12.5 mg hyperbaric bupivacaine, injected intrathecally at L3-L4 or L4-L5 in the sitting position.

  • DrugHyperbaric bupivacaine 0.5%

    12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine given intrathecally in both groups.

06

What researchers measure

Primary outcomes

  1. Incidence of intraoperative hypotension

    Proportion of patients with a fall in mean arterial pressure of more than 20% from the pre-spinal baseline at any time during surgery.

    Time frame: During surgery: from intrathecal injection to the end of surgery (up to 3 hours)

Secondary outcomes

  1. Incidence of intraoperative bradycardia

    Proportion of patients with heart rate below 60 beats per minute at any time during surgery.

    Time frame: During surgery: from intrathecal injection to the end of surgery (up to 3 hours)

  2. Number of intraoperative hypotensive episodes

    Total count of separate episodes of mean arterial pressure fall of more than 20% from baseline per patient.

    Time frame: During surgery: from intrathecal injection to the end of surgery (up to 3 hours)

  3. Number of intraoperative bradycardic episodes

    Total count of separate episodes of heart rate below 60 beats per minute per patient.

    Time frame: During surgery: from intrathecal injection to the end of surgery (up to 3 hours)

  4. Total intraoperative phenylephrine and atropine dose

    Cumulative intravenous phenylephrine (micrograms) given for hypotension and atropine (mg) given for bradycardia.

    Time frame: During surgery: from intrathecal injection to the end of surgery (up to 3 hours)

  5. Time to two-segment regression of sensory block

    Time in minutes from intrathecal injection until the highest sensory level (pinprick) regresses by two dermatomes.

    Time frame: From intrathecal injection until regression of the highest sensory level by two dermatomes, assessed every 15 minutes up to 8 hours

07

Study locations

1 site
  • Department of Anaesthesia and Critical Care, Pakistan Institute of Medical Sciences
    Islamabad, Islamabad 44000, Pakistan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Oct 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2026
First posted
Nov 10, 2026
StartActual
Aug 1, 2025
Primary completionActual
Oct 31, 2026
CompletionActual
Oct 31, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07929818
Lead sponsor
Hussain Aziz Bhatti
Responsible party
Hussain Aziz Bhatti (Principal Investigator, Pakistan Institute of Medical Sciences) — Sponsor-investigator
First posted
Nov 10, 2026
Start date
Aug 1, 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026
Last update
Nov 10, 2026

Study contacts

Hussain Aziz Bhatti, MBBS, FCPS Trainee Anaesthesia
principal investigator · Pakistan Institute of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion